SEC Form 4 · accession 0001790340-26-000070
Immuneering Corp · IMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Diana Hausman
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 11, 2026 · 5:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001790340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $4.12 | Jun 11, 2026 | A | 33,350 | A | — | Jun 11, 2036 | Class A Common Stock | 33,350 | 33,350 | D |
Explanation of responses
- F1The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.